| 产品名称： | Quantitative Synthetic Human immunodeficiency virus 1 (HIV-1) RNA |
|---|---|
| 商品货号： | TS196415 |
| Strain： | Quantitative Synthetic Human immunodeficiency virus 1 (HIV-1) RNA |
| Applications： | ATCC® Genuine Nucleics can be used for assay development, verification, validation, monitoring of day-to-day test variation and lot-to-lot performance of molecular-based assays. The quantitative format allows for the generation of a standard curve for quantitative PCR (qPCR) to determine viral load and for other molecular biology applications. |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen Specification range: 1 x 105 to 1 x 106 copies/µL 100 µL per vial with Biomatrica RNAstable |
| Storage Conditions： | -70°C or colder |
| Intended Use： | The synthetically engineered sequence of the product constitutes intellectual property belonging to ATCC. Unauthorized use, including sequencing, modification, or reverse-engineering, of the product is expressly prohibited without prior ATCC consent. |
| Comments： | Manufactured under ISO 13485 guidance Preparation includes fragments from the 5 LTR, gag gene, pol gene (including protease, reverse transcriptase, and integrase regions), tat gene, rev gene, and nef gene. This construct also includes clinically significant mutation profiles to allow compatibility with the CDC genotyping assay patent, including 41L, 67N, 70R, 103N, 181C, 215Y, and 90M.xa0(Centers for Disease Control and Prevention. Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs. US Patent 8,592,146 dated Nov. 26, 2013) The following primers and probe can be used with this nucleic acid preparation Ref   Henrich TJ, et al. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J. Virol. Methods 186(1-2): 68-72, 2012. PubMed: 22974526:Forward: TACTGACGCTCTCGCACC Reverse: TCTCGACGCAGGACTCG Probe: CTCTCTCCTTCTAGCCTC |
| Name of Depositor： | ATCC |
| U.S. Patent： | 8,592,146 |
| U.S. Patent Number： | 8,592,146 |
| Special Collection： | RNA |
| References： | Henrich TJ, et al. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J. Virol. Methods 186(1-2): 68-72, 2012. PubMed: 22974526 Centers for Disease Control and Prevention. Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs. US Patent 8,592,146 dated Nov. 26, 2013 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Quantitative Synthetic Human immunodeficiency virus 1 (HIV-1) RNA |
|---|---|
| 商品货号： | TS196415 |
| Strain： | Quantitative Synthetic Human immunodeficiency virus 1 (HIV-1) RNA |
| Applications： | ATCC® Genuine Nucleics can be used for assay development, verification, validation, monitoring of day-to-day test variation and lot-to-lot performance of molecular-based assays. The quantitative format allows for the generation of a standard curve for quantitative PCR (qPCR) to determine viral load and for other molecular biology applications. |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen Specification range: 1 x 105 to 1 x 106 copies/µL 100 µL per vial with Biomatrica RNAstable |
| Storage Conditions： | -70°C or colder |
| Intended Use： | The synthetically engineered sequence of the product constitutes intellectual property belonging to ATCC. Unauthorized use, including sequencing, modification, or reverse-engineering, of the product is expressly prohibited without prior ATCC consent. |
| Comments： | Manufactured under ISO 13485 guidance Preparation includes fragments from the 5 LTR, gag gene, pol gene (including protease, reverse transcriptase, and integrase regions), tat gene, rev gene, and nef gene. This construct also includes clinically significant mutation profiles to allow compatibility with the CDC genotyping assay patent, including 41L, 67N, 70R, 103N, 181C, 215Y, and 90M.xa0(Centers for Disease Control and Prevention. Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs. US Patent 8,592,146 dated Nov. 26, 2013) The following primers and probe can be used with this nucleic acid preparation Ref Henrich TJ, et al. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J. Virol. Methods 186(1-2): 68-72, 2012. PubMed: 22974526:Forward: TACTGACGCTCTCGCACC Reverse: TCTCGACGCAGGACTCG Probe: CTCTCTCCTTCTAGCCTC |
| Name of Depositor： | ATCC |
| U.S. Patent： | 8,592,146 |
| U.S. Patent Number： | 8,592,146 |
| Special Collection： | RNA |
| References： | Henrich TJ, et al. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J. Virol. Methods 186(1-2): 68-72, 2012. PubMed: 22974526 Centers for Disease Control and Prevention. Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs. US Patent 8,592,146 dated Nov. 26, 2013 |
